Drug Search Results
Using advanced filters...
Advanced Search [+]

Lavoltidine

Alternative Names: lavoltidine
Latest Update: 2017-01-19
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: H2 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Gastroesophageal Reflux|Esophagitis, Peptic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

LAV104616

P2

Completed

Gastroesophageal Reflux|Esophagitis, Peptic

2007-03-01

LAV110285

P1

Completed

Gastroesophageal Reflux|Esophagitis, Peptic

None

Recent News Events

Date

Type

Title